검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pegylated Liposomal Doxorubicin Hydrochloride (Pegylated Liposomal Doxorubicin Hydrochloride) AGO Research GmbH·Recurrent Platinum-Sensitive Fallo… 68 trials |
|---|---|
Overview Program | Pegylated Liposomal Doxorubicin Hydrochloride |
Overview Company | AGO Research GmbH |
Overview Modality | ADC |
Overview Target | Recurrent Platinum-Sensitive Fallopian T |
Overview Indication | Plasma Cell Leukemia |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.. Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery … |
Clinical OS | 30.8 |
Clinical Result source | ClinicalTrials.gov NCT00103506 |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pegylated Liposomal Doxorubicin Hydrochloride (Pegylated Liposomal Doxorubicin Hydrochloride) AGO Research GmbH·Recurrent Platinum-Sensitive Fallo… 68 trials |
|---|---|
Overview Program | Pegylated Liposomal Doxorubicin Hydrochloride |
Overview Company | AGO Research GmbH |
Overview Modality | ADC |
Overview Target | Recurrent Platinum-Sensitive Fallopian T |
Overview Indication | Plasma Cell Leukemia |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.. Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery … |
Clinical OS | 30.8 |
Clinical Result source | ClinicalTrials.gov NCT00103506 |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교